Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Sareum (SAR)

Price 80.00p on 22-09-2023 at 16:30:03
Change 0.00p 0%
Buy 85.00p
Sell 75.00p
Buy / Sell SAR Shares
Last Trade: Sell 20,000.00 at 77.50p
Day's Volume: 56,988
Last Close: 80.00p
Open: 80.00p
Day's Range 79.00p - 80.00p
52wk Range: 57.50p - 237.50p
Market Capitalisation: £56m
VWAP: 79.74371p
Shares in Issue: 70m

Recent Trades History Sareum (SAR)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 20,000 77.50p Ordinary
15:27:59 - 22-Sep-23
Buy* 800 81.00p Ordinary
15:19:41 - 22-Sep-23
Buy* 5,561 80.45p Ordinary
14:41:07 - 22-Sep-23
Buy* 781 80.45p Ordinary
14:32:48 - 22-Sep-23
Buy* 4,000 80.45p Ordinary
14:21:29 - 22-Sep-23
Buy* 2,500 80.45p Ordinary
13:18:53 - 22-Sep-23
Buy* 867 80.50p Ordinary
11:31:11 - 22-Sep-23
Buy* 310 80.50p Ordinary
10:14:49 - 22-Sep-23
Sell* 400 78.16p Ordinary
10:06:16 - 22-Sep-23
Sell* 3,000 79.00p Uncrossing Trade
10:00:11 - 22-Sep-23

Share Price History for Sareum

Time period:
Date Open High Low Close Volume

Share News for Sareum

Sareum begins dosing participants in phase 1a trial for SDC-1801

4th Sep 2023 09:18

(Alliance News) - Sareum Holdings PLC on Monday said it has successfully started the multiple ascending dose part of its phase 1a clinical trial for its SDC-1801 drug, following approval from the safety review committee. Read More

Sareum flagship drug trial progressing well ahead of annual results

16th Aug 2023 13:13

(Alliance News) - Sareum Holdings PLC on Wednesday said a clinical trial for its main therapeutic is continuing as planned, and it hopes to use a new prepayment facility to further enhance development. Read More

IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global

3rd Aug 2023 14:16

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs. Read More

TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment

26th Jun 2023 17:33

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News: Read More

IN BRIEF: Sareum doses first subjects in psoriasis drug trial

6th Jun 2023 13:36

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered